Ani Pharmaceuticals (ANIP) Cash from Financing Activities (2010 - 2026)

Ani Pharmaceuticals has disclosed Cash from Financing Activities across 17 years of filings, most recently posting -$4.6 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 166.0% year-over-year to -$4.6 million; the TTM figure through Jun 2026 stood at -$24.6 million (down 108.95% YoY), while the FY2025 annual figure was -$9.9 million, down 103.75% from the prior year.
• Cash from Financing Activities came in at -$4.6 million for Q2 2026 at Ani Pharmaceuticals, up from -$21.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $291.0 million in Q3 2024 to a low of -$21.6 million in Q1 2026.
• Average Cash from Financing Activities over 5 years is $16.2 million, with a median of -$2.0 million recorded in 2022.
• Year-over-year, Cash from Financing Activities plunged 2246.06% in 2023 and surged 7650.47% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$508000.0 in 2022, then sank by 2246.06% to -$11.9 million in 2023, then soared by 58.83% to -$4.9 million in 2024, then rose by 5.52% to -$4.6 million in 2025, then slipped by 0.24% to -$4.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$4.6 million in Q2 2026, -$21.6 million in Q1 2026, and -$4.6 million in Q4 2025.